Pyrazolo[4,3-d]pyrimidine compounds bind the colchicine site on tubulin to inhibit microtubule assembly and overcome multidrug resistance.
Modifying parent structures with fused rings and substituents overcomes the lack of YAP-TEAD activity in existing compounds.
Amide compounds act as substrates for fatty acid-amide hydrolase to liberate active thyromimetics, reducing cardiotoxicity risks.
Segmented molecules cross the blood-brain barrier to detect amyloids, resolving solubility and permeability trade-offs.
Oxidized mixed cyclic phenol sulfides function as active ingredients in color toners to deliver rapid charging risetime and high charge amounts.
Segmenting the molecule mitigates internal charge transfer loss, enabling lower driving voltage and extended device lifetime.
Selenium compounds inhibit inositol monophosphatase, reducing lithium toxicity while crossing the blood-brain barrier.
A PROTAC compound links a bromodomain inhibitor to an E3 ligase binder for targeted protein degradation.
Selective solubility in methanol removes diacid and tetraacid impurities, raising purity above 97% for stable polyetherimide production.
Novel molecular glue compounds bridge target proteins to E3 ligases, triggering specific degradation pathways.
A polymerizable composition with perfluoropolyether structure forms an antireflection film that repels oil-and-fat components.
Two-photon fluorescent probes selectively stain acidic vesicles in live cells with high intensity.
A fluoranthene derivative with electron-accepting nitrogen groups facilitates efficient charge transport in organic thin-film light emitting devices.
Fused ring synthetic compounds resist plasma degradation while inhibiting MRGPRX2 activation to treat pseudo allergic reactions.
Introducing heteroazole rings into pyridinium cores lowers reduction potential while maintaining chemical stability against decomposition.
Single copolymerizable molecules merge UV absorption and yellow coloration, eliminating multiple additive complexity.
Pyrazolo[4,3-e]upyranyl derivatives resist enzymatic degradation while maintaining high P2X3 receptor specificity.
Trifluoromethylpyruvamide zinc-binding groups stabilize hydrate forms in HDAC inhibitors, reducing rapid metabolism and off-target effects.